Current version snapshot

FDA-approved↗↗↗↗↗↗Endocrine↗

Current · version 4: Leuprolide↗

Related names recorded in this version: Leuprolide acetate, Lupron, Eligard, Vobrig↗↗↗↗

A GnRH agonist FDA-approved since 1985 under several names. The cited Eligard label covers advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.↗↗↗↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 15, 2026

We re-based this profile on the current Eligard label on DailyMed (SPL version 19, published May 11, 2026), because the generic label cited before is no longer marketed or served, and now describe the studies that label reports. HERO is described only as a trial in which leuprolide was the comparison treatment. Earlier versions remain available. 15

What this version reported

The cited Eligard label describes four open-label studies that measured testosterone suppression in men with prostate cancer. Each leuprolide product has its own label and uses.↗

Organizations named in cited records:
  • U.S. National Library of Medicine↗
  • U.S. Food and Drug Administration↗↗

Reader guide in this version

Key takeaway

Leuprolide is a lab-made version of gonadotropin-releasing hormone (GnRH) that, after an initial rise, suppresses the body’s production of testosterone and estrogen.1 It has been FDA-approved since 1985 and is sold under several names, including Lupron, Lupron Depot, Eligard and Fensolvi. The label cited here is Eligard’s, which covers advanced prostate cancer.1,2,3,5,6 On August 26, 2026, FDA approved another leuprolide product, Vobrig, for central precocious puberty in children.7,9

At a glance

What it is
A GnRH agonist. The Eligard label describes leuprolide acetate as a synthetic nonapeptide analogue of GnRH that is more potent than the natural hormone.1
FDA status
FDA-approved. Drugs@FDA lists Lupron with an original approval date of April 9, 1985, and Eligard with one of January 23, 2002, among many leuprolide applications. The cited Eligard label has no boxed warning.1,2,5
Human evidence
Four open-label studies described in the Eligard label, which measured whether testosterone fell to castrate levels in men with prostate cancer.1
Evidence strength
Limited human data

What is leuprolide?

Leuprolide is a lab-made peptide of nine amino acids modelled on gonadotropin-releasing hormone (GnRH). The Eligard label states that it is more potent than the natural hormone.1

Drugs@FDA lists many leuprolide applications, including Lupron (1985), Lupron Depot (1989), Lupron Depot-Ped (1993), Eligard (2002), Fensolvi (2020) and Vobrig (2026).2,3,4,5,6,9

How does leuprolide work?

The label states that leuprolide acts as an inhibitor of gonadotropin secretion when given continuously: after an initial stimulation, it suppresses the production of sex hormones by the testes and ovaries, an effect that is reversible when treatment stops.1

According to the label, testosterone first rises and then falls to the range seen in surgically castrated men about three weeks after treatment starts.1

What do human studies show?

The Eligard label describes four open-label studies in men with prostate cancer, one for each of its formulations, with 120, 117, 90 and 111 participants. The main measure was whether testosterone fell to castrate levels and stayed there.1

At the end of each study, 99% to 100% of the men evaluated had testosterone at castrate levels, and prostate-specific antigen (PSA) fell in every man whose level was raised at the start, according to the label.1

The label reports hormone and PSA results from these studies; it does not report survival or cancer progression.1

Leuprolide was also the comparison treatment in HERO, a randomized trial of another drug, relugolix, in 930 men with advanced prostate cancer. Sustained testosterone suppression was reported in 88.8% of the leuprolide group and 96.7% of the relugolix group.8

What the evidence base contains

  • Small, short, or incompletely reported human study Four open-label studies described in the Eligard label, one for each of its formulations, in 120, 117, 90 and 111 men with prostate cancer, with suppression of testosterone to castrate levels as the main measure.1

Evidence-strength label: Limited human data. How this label is assigned

Is leuprolide FDA-approved?

Yes. Drugs@FDA lists Lupron, application NDA019010, with an original approval date of April 9, 1985, followed by Lupron Depot on January 26, 1989, Lupron Depot-Ped on April 16, 1993, Eligard (NDA021343) on January 23, 2002 and Fensolvi on May 1, 2020.2,3,4,5,6

The Eligard label cited here (DailyMed SPL version 19, published May 11, 2026) states that it is indicated for the treatment of advanced prostate cancer. Other leuprolide products carry their own labels and uses.1

That label has no boxed warning. It states that Eligard is contraindicated in people allergic to GnRH, GnRH agonists or any of its components.1

Its warnings cover a temporary worsening of prostate cancer symptoms when testosterone first rises, including cases of urinary blockage and spinal cord compression; high blood sugar and diabetes; heart attack, sudden cardiac death and stroke reported with GnRH agonists in men; changes in heart rhythm; convulsions; severe skin reactions; and possible harm to a fetus.1

On August 26, 2026, FDA approved Vobrig (leuprolide acetate), from Sun Pharmaceutical Industries, for the treatment of central precocious puberty in children, according to the approval letter. Drugs@FDA lists its application, NDA213225, with that original approval date.7,9

Timeline

  1. FDA approves Lupron, the first leuprolide product, according to Drugs@FDA.2
  2. FDA approves Lupron Depot, according to Drugs@FDA.3
  3. FDA approves Eligard, according to Drugs@FDA.5
  4. Results of the HERO trial, with leuprolide as the comparison treatment, are published.8
  5. FDA approves Fensolvi, according to Drugs@FDA.6
  6. DailyMed publishes the Eligard label version cited on this page.1
  7. FDA approves Vobrig for central precocious puberty in children.7,9

What is still unknown?

How the Eligard label’s findings apply to other leuprolide products, which have their own labels and approved uses.1,3,7

How leuprolide affects survival compared with other treatments: the label’s studies were open-label and report testosterone and PSA, and HERO measured testosterone suppression rather than survival.1,8

Sources for this version

  1. 1
    ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA020263 · original submission status AP · 1993-04-16 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA213150 · original submission status AP · 2020-05-01 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer (HERO, 2020) · PMID 32469183 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  9. 9
    Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked November 15, 2026